Credo

Credo Diagnostics Biomedical is a Singapore-based medical technology company specializing in rapid molecular diagnostic solutions for point-of-care (POC) applications. The company's core technology, the VitaPCR platform, enables high-accuracy polymerase chain reaction (PCR) testing in under 20 minutes, bridging the gap between laboratory-grade results and immediate clinical needs. Their product portfolio includes assays for a variety of infectious diseases, including COVID-19, Influenza A&B, and RSV. Credo focuses on decentralizing healthcare by providing portable, easy-to-use diagnostic tools for clinics, hospitals, and emergency departments. The company maintains significant R&D and manufacturing operations in Taiwan to support its global distribution network. By simplifying complex molecular procedures, Credo aims to improve patient management through timely and actionable diagnostic information.